Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MUHAMMAD IRFAN

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1972570489
CMS profile
44336
Location
TOMBALL, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,222.37

56 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,009.42 50
Education $212.95 6

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MUHAMMAD IRFAN

NPI 1972570489 · CMS profile ID 44336

Allopathic & Osteopathic Physicians / Internal Medicine

TOMBALL, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972570489?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MUHAMMAD IRFAN, NPI 1972570489, CMS profile ID 44336. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972570489?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MUHAMMAD IRFAN, NPI 1972570489, CMS profile ID 44336. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972570489?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MUHAMMAD IRFAN, NPI 1972570489, CMS profile ID 44336, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1972570489?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

56 matching records · $1,222.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 56 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–56 of 56.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amarin Pharma Inc. $17.5402/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815279237 CMS
DEXCOM, INC. $20.1902/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845282019 CMS
AbbVie Inc. $14.1801/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794917507 CMS
Amgen Inc. $13.8901/25/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826536751 CMS
Abbott Laboratories $18.9701/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818396987 CMS
Genentech USA, Inc. $12.0101/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835955345 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $400.16 20
PY2020 $622.68 33
PY2021 $1,222.37 56
PY2022 $789.55 54
PY2023 $358.24 24
PY2024 $527.04 30
PY2025 $468.51 27

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,820.77 9
PY2025 Principal investigator $4,586,682.38 621
PY2024 Principal investigator $5,884,888.71 693
PY2023 Recipient $47,520.72 7
PY2023 Principal investigator $10,339,998.16 3,722
PY2022 Recipient $1,324.00 1
PY2022 Principal investigator $7,282,013.18 1,802
PY2021 Principal investigator $1,711,300.83 201
PY2020 Principal investigator $376,584.96 63
PY2019 Principal investigator $438,128.06 83

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

630 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $55,096.95 12/31/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228806349
Principal investigator 1 ModernaTX, Inc. $320.65 12/29/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992544
Principal investigator 1 ModernaTX, Inc. $245.13 12/29/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992676
Principal investigator 1 ModernaTX, Inc. $209.35 12/29/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992678
Principal investigator 1 ModernaTX, Inc. $99.38 12/29/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992680
Principal investigator 1 ModernaTX, Inc. $265.00 12/29/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992690
Principal investigator 1 PFIZER INC. $8,546.28 12/23/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228816912
Principal investigator 1 ModernaTX, Inc. $2,351.85 12/19/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992412
Principal investigator 1 ModernaTX, Inc. $1,772.82 12/19/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992416
Principal investigator 1 ModernaTX, Inc. $166.14 12/19/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992420
Principal investigator 1 ModernaTX, Inc. $6,889.88 12/19/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992422
Principal investigator 1 ModernaTX, Inc. $368.00 12/19/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992428
Principal investigator 1 ModernaTX, Inc. $483.86 12/19/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992538
Principal investigator 1 ModernaTX, Inc. $83.10 12/19/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992572
Principal investigator 1 ModernaTX, Inc. $100.00 12/19/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992816
Principal investigator 1 ModernaTX, Inc. $3,012.00 12/19/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992818
Principal investigator 1 ModernaTX, Inc. $198.75 12/19/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992834
Principal investigator 1 ModernaTX, Inc. $100.00 12/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992404
Principal investigator 1 ModernaTX, Inc. $90.63 12/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992568
Principal investigator 1 ModernaTX, Inc. $95.40 12/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992694
Principal investigator 1 ModernaTX, Inc. $12,023.61 12/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992776
Principal investigator 1 ModernaTX, Inc. $364.38 12/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992810
Principal investigator 1 ModernaTX, Inc. $11,631.04 12/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992852
Principal investigator 1 PFIZER INC. $53,768.00 12/17/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228707800
Principal investigator 1 PFIZER INC. $25,733.39 12/17/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228816635
Principal investigator 1 PFIZER INC. $59,823.96 12/16/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228816972
Principal investigator 1 ModernaTX, Inc. $626.00 12/15/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992454
Principal investigator 1 ModernaTX, Inc. $4,000.00 12/15/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992600
Principal investigator 1 ModernaTX, Inc. $2,000.00 12/15/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009760
Principal investigator 1 Bavarian Nordic A/S $483.63 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214142
Principal investigator 1 Bavarian Nordic A/S $430.63 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214148
Principal investigator 1 Bavarian Nordic A/S $483.63 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214252
Principal investigator 1 ModernaTX, Inc. $4,642.87 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992470
Principal investigator 1 ModernaTX, Inc. $377.63 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992606
Principal investigator 1 ModernaTX, Inc. $159.00 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992620
Principal investigator 1 ModernaTX, Inc. $20,822.00 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992622
Principal investigator 1 ModernaTX, Inc. $2,196.88 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992628
Principal investigator 1 ModernaTX, Inc. $10,272.00 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992742
Principal investigator 1 ModernaTX, Inc. $271.64 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992746
Principal investigator 1 ModernaTX, Inc. $17,563.00 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992754
Principal investigator 1 ModernaTX, Inc. $106.00 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992756
Principal investigator 1 ModernaTX, Inc. $152.38 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992764
Principal investigator 1 ModernaTX, Inc. $2,438.00 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992766
Principal investigator 1 ModernaTX, Inc. $2,475.14 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992840
Principal investigator 1 ModernaTX, Inc. $3,258.50 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992844
Principal investigator 1 ModernaTX, Inc. $92.75 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992856
Principal investigator 1 Novavax Inc $630.00 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. No dispute reported 06/30/2026 1242918935
Principal investigator 1 Novavax Inc $86,024.69 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. No dispute reported 06/30/2026 1242919692
Principal investigator 1 Novavax Inc $560.00 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. No dispute reported 06/30/2026 1242919696
Principal investigator 1 Novavax Inc $251,795.16 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. No dispute reported 06/30/2026 1242920170
Principal investigator 1 Novavax Inc $5,800.00 12/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. No dispute reported 06/30/2026 1242921038
Principal investigator 1 PFIZER INC. $20,350.00 12/12/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228806411
Principal investigator 1 ModernaTX, Inc. $1,060.00 12/10/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992478
Principal investigator 1 ModernaTX, Inc. $9,335.00 12/10/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992770
Principal investigator 1 PFIZER INC. $57.20 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704450
Principal investigator 1 PFIZER INC. $13.00 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704550
Principal investigator 1 PFIZER INC. $167.03 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704552
Principal investigator 1 PFIZER INC. $41.75 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704554
Principal investigator 1 PFIZER INC. $68.13 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704626
Principal investigator 1 PFIZER INC. $41.75 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704628
Principal investigator 1 PFIZER INC. $8.00 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704672
Principal investigator 1 PFIZER INC. $77.07 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704674
Principal investigator 1 PFIZER INC. $68.46 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704676
Principal investigator 1 PFIZER INC. $77.07 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704678
Principal investigator 1 PFIZER INC. $68.46 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704680
Principal investigator 1 PFIZER INC. $95.96 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704682
Principal investigator 1 PFIZER INC. $8.00 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704736
Principal investigator 1 PFIZER INC. $13.00 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704738
Principal investigator 1 PFIZER INC. $90.66 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704740
Principal investigator 1 PFIZER INC. $81.51 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704742
Principal investigator 1 PFIZER INC. $77.07 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704820
Principal investigator 1 PFIZER INC. $80.06 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704822
Principal investigator 1 PFIZER INC. $96.95 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704824
Principal investigator 1 PFIZER INC. $8.00 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704872
Principal investigator 1 PFIZER INC. $13.00 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704874
Principal investigator 1 PFIZER INC. $90.66 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704920
Principal investigator 1 PFIZER INC. $76.41 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704922
Principal investigator 1 PFIZER INC. $8.00 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704924
Principal investigator 1 PFIZER INC. $95.96 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704980
Principal investigator 1 PFIZER INC. $81.51 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705022
Principal investigator 1 PFIZER INC. $110.33 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705046
Principal investigator 1 PFIZER INC. $95.96 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705048
Principal investigator 1 PFIZER INC. $99.27 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228705110
Principal investigator 1 PFIZER INC. $81.51 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705112
Principal investigator 1 PFIZER INC. $110.33 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705168
Principal investigator 1 PFIZER INC. $120.93 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228705216
Principal investigator 1 PFIZER INC. $99.73 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705218
Principal investigator 1 PFIZER INC. $90.66 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705220
Principal investigator 1 PFIZER INC. $90.66 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705232
Principal investigator 1 PFIZER INC. $109.79 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705334
Principal investigator 1 PFIZER INC. $81.51 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705336
Principal investigator 1 PFIZER INC. $110.33 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705352
Principal investigator 1 PFIZER INC. $80.06 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705354
Principal investigator 1 PFIZER INC. $96.62 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228705406
Principal investigator 1 PFIZER INC. $13.00 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705408
Principal investigator 1 PFIZER INC. $68.46 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705410
Principal investigator 1 PFIZER INC. $80.06 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705534
Principal investigator 1 PFIZER INC. $88.00 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228705536
Principal investigator 1 PFIZER INC. $41.75 12/06/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705538
Principal investigator 1 Bavarian Nordic A/S $231.88 12/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214144
Principal investigator 1 Bavarian Nordic A/S $475.86 12/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214150
Principal investigator 1 Bavarian Nordic A/S $430.63 12/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214154
Principal investigator 1 Bavarian Nordic A/S $470.38 12/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214156
Principal investigator 1 Bavarian Nordic A/S $470.38 12/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214250
Principal investigator 1 ABBVIE INC. $409.50 12/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202527058
Principal investigator 1 ABBVIE INC. $1,656.93 12/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202527262
Principal investigator 1 AstraZeneca Pharmaceuticals LP $28,777.00 12/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185538384
Principal investigator 1 ModernaTX, Inc. $3,852.00 12/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992480
Principal investigator 1 ModernaTX, Inc. $2,665.92 12/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992616
Principal investigator 1 ModernaTX, Inc. $150.00 12/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992636
Principal investigator 1 ModernaTX, Inc. $3,241.02 12/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992638
Principal investigator 1 ModernaTX, Inc. $2,250.00 12/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992648
Principal investigator 1 ModernaTX, Inc. $720.00 12/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992662
Principal investigator 1 ModernaTX, Inc. $1,636.40 12/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992848
Principal investigator 1 ModernaTX, Inc. $12,840.00 12/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992854
Principal investigator 1 ModernaTX, Inc. $3,000.00 12/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992868
Principal investigator 1 ModernaTX, Inc. $397.50 12/01/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992510
Principal investigator 1 Novavax Inc $2,000.00 12/01/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. No dispute reported 06/30/2026 1242920173
Principal investigator 1 Novavax Inc $500.00 12/01/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. No dispute reported 06/30/2026 1242921035
Principal investigator 1 Novavax Inc $1,968.87 12/01/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. No dispute reported 06/30/2026 1242921042
Principal investigator 1 Novavax Inc $10,900.00 12/01/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. No dispute reported 06/30/2026 1242921831
Principal investigator 1 ModernaTX, Inc. $483.86 11/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992414
Principal investigator 1 ModernaTX, Inc. $83.10 11/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992550
Principal investigator 1 ModernaTX, Inc. $775.32 11/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992564
Principal investigator 1 ModernaTX, Inc. $9,407.40 11/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992684
Principal investigator 1 ModernaTX, Inc. $7,091.28 11/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992714
Principal investigator 1 ModernaTX, Inc. $1,722.47 11/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992820
Principal investigator 1 ModernaTX, Inc. $132.50 11/26/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992418
Principal investigator 1 ModernaTX, Inc. $38.43 11/26/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992554
Principal investigator 1 ModernaTX, Inc. $47.70 11/26/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992698
Principal investigator 1 ModernaTX, Inc. $64.93 11/26/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992830
Principal investigator 1 PFIZER INC. $15,205.41 11/26/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228707804
Principal investigator 1 PFIZER INC. $39,232.07 11/26/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228817940
Principal investigator 1 PFIZER INC. $100.00 11/25/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228817948
Principal investigator 1 ModernaTX, Inc. $6,896.51 11/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992444
Principal investigator 1 ModernaTX, Inc. $7,342.74 11/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992452
Principal investigator 1 ModernaTX, Inc. $466.95 11/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992458
Principal investigator 1 ModernaTX, Inc. $3,340.38 11/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992586
Principal investigator 1 ModernaTX, Inc. $7,240.72 11/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992588
Principal investigator 1 ModernaTX, Inc. $1,228.80 11/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992590
Principal investigator 1 ModernaTX, Inc. $2,349.27 11/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992592
Principal investigator 1 ModernaTX, Inc. $2,791.20 11/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992594
Principal investigator 1 ModernaTX, Inc. $3,841.49 11/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992598
Principal investigator 1 ModernaTX, Inc. $1,105.02 11/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992602
Principal investigator 1 ModernaTX, Inc. $2,789.80 11/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992604
Principal investigator 1 ModernaTX, Inc. $8,621.72 11/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992726
Principal investigator 1 ModernaTX, Inc. $4,342.52 11/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992728
Principal investigator 1 ModernaTX, Inc. $6,437.40 11/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992736
Principal investigator 1 ModernaTX, Inc. $4,141.54 11/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992838
Principal investigator 1 ModernaTX, Inc. $7,700.00 11/21/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992472
Principal investigator 1 ModernaTX, Inc. $2,000.00 11/21/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992748
Principal investigator 1 ModernaTX, Inc. $2,800.00 11/21/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992752
Principal investigator 1 ModernaTX, Inc. $997.72 11/21/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992786
Principal investigator 1 Novavax Inc $94.83 11/21/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. No dispute reported 06/30/2026 1242920595
Principal investigator 1 PFIZER INC. $5,697.52 11/20/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228818382
Principal investigator 1 PFIZER INC. $2,009.15 11/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228818900
Principal investigator 1 PFIZER INC. $19,148.58 11/18/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228817954
Principal investigator 1 PFIZER INC. $9,970.66 11/15/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228818393
Principal investigator 1 PFIZER INC. $32,551.90 11/13/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228707978
Principal investigator 1 Bavarian Nordic A/S $470.38 11/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214140
Principal investigator 1 Bavarian Nordic A/S $613.70 11/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214158
Principal investigator 1 Bavarian Nordic A/S $4,566.88 11/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214162
Principal investigator 1 PFIZER INC. $19,941.32 11/11/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228818387
Principal investigator 1 ModernaTX, Inc. $112.62 11/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992652
Principal investigator 1 ModernaTX, Inc. $1,199.91 11/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) No dispute reported 06/30/2026 1252992672
Principal investigator 1 PFIZER INC. $123,266.08 11/05/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228707976
Principal investigator 1 PFIZER INC. $11,500.00 11/04/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228707802
Principal investigator 1 ModernaTX, Inc. $11,222.85 11/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults No dispute reported 06/30/2026 1252992394
Principal investigator 1 PFIZER INC. $2,848.76 10/30/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228825221
Principal investigator 1 ModernaTX, Inc. $186.83 10/29/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992492
Principal investigator 1 ModernaTX, Inc. $7,526.00 10/29/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992498
Principal investigator 1 ModernaTX, Inc. $466.00 10/29/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992500
Principal investigator 1 ModernaTX, Inc. $466.00 10/29/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992778
Principal investigator 1 ModernaTX, Inc. $443.88 10/29/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992780
Principal investigator 1 ModernaTX, Inc. $440.00 10/29/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992858
Principal investigator 1 ModernaTX, Inc. $315.58 10/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992570
Principal investigator 1 ModernaTX, Inc. $1,451.58 10/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992712
Principal investigator 1 ModernaTX, Inc. $69.25 10/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992826
Principal investigator 1 PFIZER INC. $87,407.34 10/25/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228823555
Principal investigator 1 Bavarian Nordic A/S $231.88 10/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214146
Principal investigator 1 ModernaTX, Inc. $10,669.12 10/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992618
Principal investigator 1 ModernaTX, Inc. $932.00 10/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992644
Principal investigator 1 ModernaTX, Inc. $79.50 10/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992646
Principal investigator 1 ModernaTX, Inc. $1,187.20 10/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992864
Principal investigator 1 ModernaTX, Inc. $76.86 10/23/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992406
Principal investigator 1 ModernaTX, Inc. $92.00 10/23/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992532
Principal investigator 1 ModernaTX, Inc. $753.00 10/23/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992576
Principal investigator 1 ModernaTX, Inc. $129.86 10/23/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992716
Principal investigator 1 PFIZER INC. $2,418.63 10/23/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704452
Principal investigator 1 PFIZER INC. $2,206.63 10/23/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704876
Principal investigator 1 PFIZER INC. $2,206.63 10/23/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705050
Principal investigator 1 PFIZER INC. $2,418.63 10/23/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228705114
Principal investigator 1 PFIZER INC. $1,073.75 10/23/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228705350
Principal investigator 1 ModernaTX, Inc. $6,244.53 10/22/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992474
Principal investigator 1 ModernaTX, Inc. $6,345.44 10/22/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992874
Principal investigator 1 ModernaTX, Inc. $3,572.55 10/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults No dispute reported 06/30/2026 1252992522
Principal investigator 1 ModernaTX, Inc. $50.00 10/15/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992526
Principal investigator 1 ModernaTX, Inc. $76.86 10/15/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992528
Principal investigator 1 ModernaTX, Inc. $129.86 10/15/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992546
Principal investigator 1 ModernaTX, Inc. $132.50 10/15/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992548
Principal investigator 1 ModernaTX, Inc. $753.00 10/15/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992722
Principal investigator 1 ModernaTX, Inc. $92.00 10/15/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992806
Principal investigator 1 PFIZER INC. $28,487.60 10/11/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228825153
Principal investigator 1 ABBVIE INC. $1,349.13 10/09/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202514201
Principal investigator 1 Bavarian Nordic A/S $470.38 10/08/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214152
Principal investigator 1 ModernaTX, Inc. $132.50 10/08/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992574
Principal investigator 1 ModernaTX, Inc. $276.00 10/08/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992706
Principal investigator 1 ModernaTX, Inc. $2,259.00 10/08/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992724
Principal investigator 1 ModernaTX, Inc. $75.00 10/08/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992824
Principal investigator 1 PFIZER INC. $574.00 10/06/2025 Non-covered Recipient Entity
DM Clinical Research Cyfair
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228719322
Principal investigator 1 ModernaTX, Inc. $331.25 10/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992400
Principal investigator 1 ModernaTX, Inc. $25.00 10/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992682
Principal investigator 1 ModernaTX, Inc. $2,259.00 10/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992686
Principal investigator 1 ModernaTX, Inc. $276.00 10/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992688
Principal investigator 1 ModernaTX, Inc. $286.20 10/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992704
Principal investigator 1 ModernaTX, Inc. $357.00 10/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992730
Principal investigator 1 Bavarian Nordic A/S $503.51 10/01/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214160
Principal investigator 1 Bavarian Nordic A/S $364.88 10/01/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214164
Principal investigator 1 PFIZER INC. $861.00 10/01/2025 Non-covered Recipient Entity
DM Clinical Research Cyfair
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228719324
Principal investigator 1 PFIZER INC. $2,168.00 09/30/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228827747
Principal investigator 1 ModernaTX, Inc. $1,451.58 09/29/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992530
Principal investigator 1 ModernaTX, Inc. $13.85 09/29/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992552
Principal investigator 1 PFIZER INC. $757.50 09/29/2025 Non-covered Recipient Entity
DM Clinical Research Cyfair
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228807554
Principal investigator 1 PFIZER INC. $615.50 09/29/2025 Non-covered Recipient Entity
DM Clinical Research Cyfair
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228807560
Principal investigator 1 PFIZER INC. $35.00 09/27/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704800
Principal investigator 1 PFIZER INC. $1,350.00 09/27/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704806
Principal investigator 1 PFIZER INC. $35.00 09/27/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704964
Principal investigator 1 PFIZER INC. $600.00 09/27/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705008
Principal investigator 1 PFIZER INC. $35.00 09/27/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705098
Principal investigator 1 PFIZER INC. $35.00 09/27/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705100
Principal investigator 1 PFIZER INC. $38,458.26 09/27/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228825872
Principal investigator 1 ModernaTX, Inc. $2,870.79 09/26/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992462
Principal investigator 1 ABBVIE INC. $72.00 09/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202512326
Principal investigator 1 PFIZER INC. $738.60 09/25/2025 Non-covered Recipient Entity
DM Clinical Research CyFair
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228814529
Principal investigator 1 PFIZER INC. $819.02 09/25/2025 Non-covered Recipient Entity
DM Clinical Research CyFair
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228814534
Principal investigator 1 ModernaTX, Inc. $33.75 09/24/2025 Non-covered Recipient Entity
CYFAIR
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992426
Principal investigator 1 ModernaTX, Inc. $12,489.06 09/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992464
Principal investigator 1 ModernaTX, Inc. $2,651.36 09/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992634
Principal investigator 1 ModernaTX, Inc. $1,221.67 09/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992860
Principal investigator 1 ModernaTX, Inc. $1,987.50 09/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992880
Principal investigator 1 PFIZER INC. $1,722.00 09/24/2025 Non-covered Recipient Entity
DM Clinical Research Cyfair
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228719320
Principal investigator 1 PFIZER INC. $25,714.08 09/24/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228825836
Principal investigator 1 PFIZER INC. $7,300.56 09/24/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228826864
Principal investigator 1 ModernaTX, Inc. $374.98 09/19/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992504
Principal investigator 1 ModernaTX, Inc. $1,841.77 09/19/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992632
Principal investigator 1 ModernaTX, Inc. $18,009.43 09/19/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992656
Principal investigator 1 Bavarian Nordic A/S $251.75 09/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214174
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,456.55 09/10/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067625
Principal investigator 1 PFIZER INC. $31,336.36 09/09/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228826160
Principal investigator 1 Bavarian Nordic A/S $430.63 09/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214166
Principal investigator 1 ModernaTX, Inc. $422.63 09/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) No dispute reported 06/30/2026 1252992398
Principal investigator 1 ModernaTX, Inc. $500.00 09/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992442
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992446
Principal investigator 1 ModernaTX, Inc. $800.00 09/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992448
Principal investigator 1 ModernaTX, Inc. $995.94 09/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992450
Principal investigator 1 ModernaTX, Inc. $3,450.00 09/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992456
Principal investigator 1 ModernaTX, Inc. $1,600.00 09/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992596
Principal investigator 1 ModernaTX, Inc. $1,000.00 09/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992732
Principal investigator 1 ModernaTX, Inc. $750.00 09/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992740
Principal investigator 1 PFIZER INC. $10,832.25 09/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228827739
Principal investigator 1 SANOFI US SERVICES INC. $300.00 09/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226135737
Principal investigator 1 SANOFI US SERVICES INC. $5,216.00 09/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226135741
Principal investigator 1 Bavarian Nordic A/S $4,638.26 09/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214108
Principal investigator 1 Bavarian Nordic A/S $2,633.38 09/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214126
Principal investigator 1 ModernaTX, Inc. $4,759.35 09/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992502
Principal investigator 1 ModernaTX, Inc. $193.83 08/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992556
Principal investigator 1 ModernaTX, Inc. $180.00 08/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992702
Principal investigator 1 ModernaTX, Inc. $483.86 08/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992710
Principal investigator 1 ModernaTX, Inc. $2,351.85 08/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992808
Principal investigator 1 ModernaTX, Inc. $6,889.88 08/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992828
Principal investigator 1 ModernaTX, Inc. $83.10 08/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992832
Principal investigator 1 ModernaTX, Inc. $3,545.64 08/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992836
Principal investigator 1 ModernaTX, Inc. $7,113.60 08/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009756
Principal investigator 1 ModernaTX, Inc. $397.50 08/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992876
Principal investigator 1 PFIZER INC. $16,123.97 08/27/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228830457
Principal investigator 1 Amgen Inc. $1,248.00 08/25/2025 Non-covered Recipient Entity
DM CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM No dispute reported 06/30/2026 1246640851
Principal investigator 1 ModernaTX, Inc. $1,506.00 08/22/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992430
Principal investigator 1 ModernaTX, Inc. $550.00 08/22/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992436
Principal investigator 1 ModernaTX, Inc. $184.00 08/22/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992540
Principal investigator 1 ModernaTX, Inc. $2,500.00 08/22/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992560
Principal investigator 1 ModernaTX, Inc. $1,750.00 08/22/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992566
Principal investigator 1 ModernaTX, Inc. $92,822.21 08/22/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992624
Principal investigator 1 ModernaTX, Inc. $265.00 08/22/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992700
Principal investigator 1 ModernaTX, Inc. $50.00 08/22/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992720
Principal investigator 1 ModernaTX, Inc. $8,165.92 08/20/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992476
Principal investigator 1 ModernaTX, Inc. $7,826.80 08/20/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992870
Principal investigator 1 ModernaTX, Inc. $484.96 08/13/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992608
Principal investigator 1 ModernaTX, Inc. $68.90 08/13/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992640
Principal investigator 1 ModernaTX, Inc. $500.86 08/13/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992642
Principal investigator 1 ModernaTX, Inc. $28,209.89 08/13/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992862
Principal investigator 1 ModernaTX, Inc. $2,318.76 08/13/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992866
Principal investigator 1 Bavarian Nordic A/S $371.63 08/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214176
Principal investigator 1 PFIZER INC. $8,546.28 08/05/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228828533
Principal investigator 1 ModernaTX, Inc. $526.11 08/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992408
Principal investigator 1 ModernaTX, Inc. $7,055.55 08/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992536
Principal investigator 1 ModernaTX, Inc. $1,722.47 08/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992542
Principal investigator 1 ModernaTX, Inc. $1,772.82 08/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992708
Principal investigator 1 SANOFI US SERVICES INC. $10,432.00 08/04/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226135705
Principal investigator 1 PFIZER INC. $1,028.20 08/02/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228830494
Principal investigator 1 Bavarian Nordic A/S $8,628.57 08/01/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214110
Principal investigator 1 Bavarian Nordic A/S $280.42 08/01/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214168
Principal investigator 1 ModernaTX, Inc. $10,087.32 08/01/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992850
Principal investigator 1 PFIZER INC. $96,164.96 08/01/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228827511
Principal investigator 1 PFIZER INC. $21,892.20 07/31/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228830597
Principal investigator 1 ModernaTX, Inc. $2,351.85 07/30/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992534
Principal investigator 1 ModernaTX, Inc. $138.45 07/30/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992718
Principal investigator 1 ModernaTX, Inc. $3,545.64 07/30/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992814
Principal investigator 1 ModernaTX, Inc. $1,150.00 07/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009746
Principal investigator 1 PFIZER INC. $4,424.81 07/26/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228830191
Principal investigator 1 ModernaTX, Inc. $255.73 07/23/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults No dispute reported 06/30/2026 1252992524
Principal investigator 1 SANOFI US SERVICES INC. $5,000.00 07/21/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226135680
Principal investigator 1 ModernaTX, Inc. $12,934.69 07/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992650
Principal investigator 1 PFIZER INC. $18,530.91 07/11/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228830658
Principal investigator 1 ModernaTX, Inc. $772.48 07/09/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992610
Principal investigator 1 ModernaTX, Inc. $1,926.00 07/09/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992614
Principal investigator 1 ModernaTX, Inc. $1,000.00 07/09/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992760
Principal investigator 1 PFIZER INC. $4,306.30 07/09/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228830048
Principal investigator 1 PFIZER INC. $201,745.90 07/08/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228830106
Principal investigator 1 Bavarian Nordic A/S $231.88 07/07/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214170
Principal investigator 1 Bavarian Nordic A/S $74.00 07/07/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214172
Principal investigator 1 ModernaTX, Inc. $728.75 07/07/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252992668
Principal investigator 1 ABBVIE INC. $1,349.13 07/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202495609
Principal investigator 1 ModernaTX, Inc. $795.00 07/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992512
Principal investigator 1 ModernaTX, Inc. $642.00 07/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992750
Principal investigator 1 ModernaTX, Inc. $106.00 07/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992768
Principal investigator 1 ModernaTX, Inc. $13,854.57 07/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992846
Principal investigator 1 ModernaTX, Inc. $636.00 07/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992884
Principal investigator 1 PFIZER INC. $346.16 07/02/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228830664
Principal investigator 1 PFIZER INC. $17,070.13 07/01/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228830186
Principal investigator 1 ModernaTX, Inc. $7,113.60 06/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009754
Principal investigator 1 PFIZER INC. $14,311.82 06/26/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228829527
Principal investigator 1 Bavarian Nordic A/S $284.88 06/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214118
Principal investigator 1 Bavarian Nordic A/S $324.63 06/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214120
Principal investigator 1 Bavarian Nordic A/S $7,583.26 06/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214236
Principal investigator 1 PFIZER INC. $55,998.45 06/21/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228829872
Principal investigator 1 ModernaTX, Inc. $200.00 06/20/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992460
Principal investigator 1 ModernaTX, Inc. $1,318.40 06/20/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992468
Principal investigator 1 Bavarian Nordic A/S $231.88 06/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214112
Principal investigator 1 Bavarian Nordic A/S $50.00 06/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214114
Principal investigator 1 Bavarian Nordic A/S $74.00 06/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214116
Principal investigator 1 ModernaTX, Inc. $19,200.00 06/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) No dispute reported 06/30/2026 1252992396
Principal investigator 1 ModernaTX, Inc. $443.04 06/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992438
Principal investigator 1 ModernaTX, Inc. $14,534.80 06/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992440
Principal investigator 1 ModernaTX, Inc. $12,224.49 06/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992514
Principal investigator 1 ModernaTX, Inc. $6,889.88 06/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992558
Principal investigator 1 ModernaTX, Inc. $2,365.20 06/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992582
Principal investigator 1 ModernaTX, Inc. $5,318.46 06/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992692
Principal investigator 1 ModernaTX, Inc. $5,309.62 06/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) No dispute reported 06/30/2026 1252992804
Principal investigator 1 ModernaTX, Inc. $354.00 06/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009744
Principal investigator 1 ModernaTX, Inc. $334,339.20 06/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009758
Principal investigator 1 ABBVIE INC. $72.00 06/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202491837
Principal investigator 1 PFIZER INC. $135.32 06/17/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704804
Principal investigator 1 PFIZER INC. $124.05 06/17/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704966
Principal investigator 1 PFIZER INC. $37.70 06/17/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705148
Principal investigator 1 PFIZER INC. $135.32 06/17/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705162
Principal investigator 1 PFIZER INC. $35.00 06/17/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705332
Principal investigator 1 Seqirus USA Inc $550.00 06/16/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296448
Principal investigator 1 Seqirus USA Inc $1,320.00 06/16/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296450
Principal investigator 1 Seqirus USA Inc $1,000.00 06/16/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296452
Principal investigator 1 Seqirus USA Inc $2,000.00 06/16/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296454
Principal investigator 1 Seqirus USA Inc $1,500.00 06/16/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296460
Principal investigator 1 Seqirus USA Inc $1,000.00 06/16/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296462
Principal investigator 1 PFIZER INC. $1,384.64 06/14/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228829810
Principal investigator 1 Bavarian Nordic A/S $798.58 06/13/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214238
Principal investigator 1 PFIZER INC. $136,889.62 06/10/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228829372
Principal investigator 1 Bavarian Nordic A/S $1,282.92 06/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214078
Principal investigator 1 ModernaTX, Inc. $1,429.75 06/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992482
Principal investigator 1 ModernaTX, Inc. $1,878.88 06/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992762
Principal investigator 1 Bavarian Nordic A/S $5,539.43 06/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214240
Principal investigator 1 PFIZER INC. $14,044.31 05/30/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228832899
Principal investigator 1 ModernaTX, Inc. $526.11 05/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992434
Principal investigator 1 ModernaTX, Inc. $5,764.18 05/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992484
Principal investigator 1 ModernaTX, Inc. $3,545.64 05/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992696
Principal investigator 1 ModernaTX, Inc. $3,655.58 05/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults No dispute reported 06/30/2026 1252992800
Principal investigator 1 ModernaTX, Inc. $9,460.80 05/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992812
Principal investigator 1 ModernaTX, Inc. $279,801.60 05/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009748
Principal investigator 1 ModernaTX, Inc. $2,478.00 05/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009752
Principal investigator 1 PFIZER INC. $184.50 05/28/2025 Non-covered Recipient Entity
DM Clin Research Houston
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228814632
Principal investigator 1 PFIZER INC. $211.65 05/28/2025 Non-covered Recipient Entity
DM Clin Research Houston
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228814681
Principal investigator 1 PFIZER INC. $1,089.15 05/27/2025 Non-covered Recipient Entity
DM Clinical ResearchCyfair
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707668
Principal investigator 1 PFIZER INC. $1,089.15 05/27/2025 Non-covered Recipient Entity
DM Clinical Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228828047
Principal investigator 1 Bavarian Nordic A/S $231.88 05/23/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214122
Principal investigator 1 Bavarian Nordic A/S $74.00 05/23/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214124
Principal investigator 1 Bavarian Nordic A/S $231.88 05/23/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214254
Principal investigator 1 Bavarian Nordic A/S $74.00 05/23/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214256
Principal investigator 1 ModernaTX, Inc. $9,867.31 05/21/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992882
Principal investigator 1 PFIZER INC. $72.61 05/21/2025 Non-covered Recipient Entity
DM Clinical ResearchCyfair
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707838
Principal investigator 1 PFIZER INC. $18.98 05/21/2025 Non-covered Recipient Entity
DM Clinical ResearchCyfair
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707842
Principal investigator 1 PFIZER INC. $18.98 05/21/2025 Non-covered Recipient Entity
DM Clinical Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228828038
Principal investigator 1 PFIZER INC. $72.61 05/21/2025 Non-covered Recipient Entity
DM Clinical Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228828056
Principal investigator 1 Bavarian Nordic A/S $5,861.88 05/16/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214106
Principal investigator 1 PFIZER INC. $88,343.40 05/15/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228832749
Principal investigator 1 ABBVIE INC. $147.00 05/13/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202484721
Principal investigator 1 ModernaTX, Inc. $499.19 05/09/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults No dispute reported 06/30/2026 1252992390
Principal investigator 1 PFIZER INC. $50,053.36 05/08/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228832912
Principal investigator 1 Bavarian Nordic A/S $231.88 05/07/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214128
Principal investigator 1 Bavarian Nordic A/S $74.00 05/07/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214130
Principal investigator 1 Bavarian Nordic A/S $430.63 05/07/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214132
Principal investigator 1 Bavarian Nordic A/S $470.38 05/07/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214222
Principal investigator 1 Bavarian Nordic A/S $231.88 05/07/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214258
Principal investigator 1 Bavarian Nordic A/S $74.00 05/07/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214260
Principal investigator 1 ABBVIE INC. $1,349.13 05/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202481565
Principal investigator 1 PFIZER INC. $615.00 05/06/2025 Non-covered Recipient Entity
DM Clin Research Houston
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228814673
Principal investigator 1 PFIZER INC. $705.50 05/06/2025 Non-covered Recipient Entity
DM Clin Research Houston
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228814687
Principal investigator 1 ModernaTX, Inc. $1,272.00 04/30/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992402
Principal investigator 1 ModernaTX, Inc. $1,166.00 04/30/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992410
Principal investigator 1 ModernaTX, Inc. $106.00 04/30/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992424
Principal investigator 1 ModernaTX, Inc. $1,060.00 04/30/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992432
Principal investigator 1 ModernaTX, Inc. $954.00 04/30/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992578
Principal investigator 1 ModernaTX, Inc. $1,696.00 04/30/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992580
Principal investigator 1 ModernaTX, Inc. $2,120.00 04/30/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992584
Principal investigator 1 ModernaTX, Inc. $4,956.00 04/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009740
Principal investigator 1 Bavarian Nordic A/S $39.75 04/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214232
Principal investigator 1 Bavarian Nordic A/S $547.45 04/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214234
Principal investigator 1 PFIZER INC. $50.00 04/25/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228833477
Principal investigator 1 Amgen Inc. $261,755.91 04/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM No dispute reported 06/30/2026 1246640983
Principal investigator 1 PFIZER INC. $245.13 04/24/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228832863
Principal investigator 1 PFIZER INC. $325.00 04/24/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228833483
Principal investigator 1 Bavarian Nordic A/S $4,626.58 04/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214242
Principal investigator 1 ModernaTX, Inc. $13,298.69 04/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992758
Principal investigator 1 ModernaTX, Inc. $4,379.13 04/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992788
Principal investigator 1 PFIZER INC. $46.38 04/18/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704858
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $80.00 04/16/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068201
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,500.00 04/16/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068203
Principal investigator 1 ModernaTX, Inc. $939.44 04/16/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992744
Principal investigator 1 PFIZER INC. $4,927.26 04/16/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228833398
Principal investigator 1 Bavarian Nordic A/S $231.88 04/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214134
Principal investigator 1 Bavarian Nordic A/S $74.00 04/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214136
Principal investigator 1 Bavarian Nordic A/S $298.75 04/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214138
Principal investigator 1 Bavarian Nordic A/S $613.70 04/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214220
Principal investigator 1 Bavarian Nordic A/S $231.88 04/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214262
Principal investigator 1 Bavarian Nordic A/S $74.00 04/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214264
Principal investigator 1 Bavarian Nordic A/S $231.88 04/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214266
Principal investigator 1 Bavarian Nordic A/S $74.00 04/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214268
Principal investigator 1 Bavarian Nordic A/S $231.88 04/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214270
Principal investigator 1 Bavarian Nordic A/S $74.00 04/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214274
Principal investigator 1 Bavarian Nordic A/S $231.88 04/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214276
Principal investigator 1 ModernaTX, Inc. $27,600.00 04/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009762
Principal investigator 1 ModernaTX, Inc. $124.80 04/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009768
Principal investigator 1 ABBVIE INC. $326.00 04/10/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202475584
Principal investigator 1 ABBVIE INC. $147.00 04/09/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202475069
Principal investigator 1 Bavarian Nordic A/S $231.88 04/09/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214218
Principal investigator 1 Bavarian Nordic A/S $74.00 04/09/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214228
Principal investigator 1 PFIZER INC. $7,321.98 04/08/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228832923
Principal investigator 1 ModernaTX, Inc. $435.00 04/04/2025 Non-covered Recipient Entity
CYFAIR
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992562
Principal investigator 1 ABBVIE INC. $1,349.13 04/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202469176
Principal investigator 1 AstraZeneca Pharmaceuticals LP $26,700.00 04/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185538380
Principal investigator 1 Bavarian Nordic A/S $430.63 04/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214224
Principal investigator 1 Bavarian Nordic A/S $7,417.06 04/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214244
Principal investigator 1 Bavarian Nordic A/S $430.63 04/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214272
Principal investigator 1 ModernaTX, Inc. $40,803.93 04/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252992388
Principal investigator 1 ModernaTX, Inc. $397.50 04/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992660
Principal investigator 1 SANOFI US SERVICES INC. $16,450.00 04/02/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226135554
Principal investigator 1 Bavarian Nordic A/S $231.88 04/01/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214226
Principal investigator 1 Bavarian Nordic A/S $4,590.22 04/01/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214246
Principal investigator 1 ModernaTX, Inc. $1,844.42 04/01/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992466
Principal investigator 1 ModernaTX, Inc. $3,210.00 04/01/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992486
Principal investigator 1 ModernaTX, Inc. $2,965.37 04/01/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992822
Principal investigator 1 PFIZER INC. $245.13 03/28/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228832839
Principal investigator 1 PFIZER INC. $25,176.97 03/28/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228833384
Principal investigator 1 Bavarian Nordic A/S $430.63 03/26/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214196
Principal investigator 1 Bavarian Nordic A/S $583.63 03/26/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214248
Principal investigator 1 ModernaTX, Inc. $8.50 03/26/2025 Non-covered Recipient Entity
CYFAIR
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252992674
Principal investigator 1 PFIZER INC. $201.19 03/26/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228833350
Principal investigator 1 ModernaTX, Inc. $1,499.68 03/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992734
Principal investigator 1 ModernaTX, Inc. $4,248.00 03/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009738
Principal investigator 1 PFIZER INC. $189.80 03/24/2025 Non-covered Recipient Entity
DM Clinical ResearchCyfair
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707758
Principal investigator 1 PFIZER INC. $189.80 03/24/2025 Non-covered Recipient Entity
DM Clinical Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228827904
Principal investigator 1 PFIZER INC. $26,496.93 03/22/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228832773
Principal investigator 1 ModernaTX, Inc. $13,885.10 03/21/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992626
Principal investigator 1 PFIZER INC. $500.00 03/20/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704794
Principal investigator 1 PFIZER INC. $500.00 03/20/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704796
Principal investigator 1 PFIZER INC. $500.00 03/20/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704958
Principal investigator 1 PFIZER INC. $2,418.63 03/20/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704960
Principal investigator 1 PFIZER INC. $500.00 03/20/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228704962
Principal investigator 1 PFIZER INC. $500.00 03/20/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705006
Principal investigator 1 PFIZER INC. $550.00 03/20/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705150
Principal investigator 1 PFIZER INC. $500.00 03/20/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705158
Principal investigator 1 PFIZER INC. $500.00 03/20/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705160
Principal investigator 1 PFIZER INC. $250.00 03/20/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705290
Principal investigator 1 PFIZER INC. $500.00 03/20/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228705518
Principal investigator 1 PFIZER INC. $550.00 03/20/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228705520
Principal investigator 1 PFIZER INC. $50,353.94 03/20/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228833333
Principal investigator 1 ModernaTX, Inc. $8,000.38 03/19/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992654
Principal investigator 1 PFIZER INC. $189.80 03/10/2025 Non-covered Recipient Entity
DM Clinical ResearchCyfair
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707483
Principal investigator 1 PFIZER INC. $189.80 03/10/2025 Non-covered Recipient Entity
DM Clinical Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228827321
Principal investigator 1 ModernaTX, Inc. $1,650.00 03/07/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992784
Principal investigator 1 Bavarian Nordic A/S $74.00 03/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214080
Principal investigator 1 Bavarian Nordic A/S $74.00 03/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214180
Principal investigator 1 Bavarian Nordic A/S $331.88 03/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214182
Principal investigator 1 Bavarian Nordic A/S $231.88 03/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214184
Principal investigator 1 Bavarian Nordic A/S $6,238.02 03/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214216
Principal investigator 1 ModernaTX, Inc. $1,130.00 03/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252992386
Principal investigator 1 ModernaTX, Inc. $1,130.00 03/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252992516
Principal investigator 1 ModernaTX, Inc. $2,250.00 03/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252992518
Principal investigator 1 ModernaTX, Inc. $950.04 03/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252992794
Principal investigator 1 ModernaTX, Inc. $14,585.41 03/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252992796
Principal investigator 1 ModernaTX, Inc. $1,300.00 03/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252992798
Principal investigator 1 PFIZER INC. $50.00 03/05/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228833338
Principal investigator 1 PFIZER INC. $5,057.57 03/04/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228832809
Principal investigator 1 PFIZER INC. $14,500.00 03/04/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228832858
Principal investigator 1 Bavarian Nordic A/S $2,961.90 03/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214230
Principal investigator 1 ModernaTX, Inc. $1,143.13 03/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults No dispute reported 06/30/2026 1252992392
Principal investigator 1 ModernaTX, Inc. $2,371.20 02/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009742
Principal investigator 1 ModernaTX, Inc. $7,080.00 02/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009764
Principal investigator 1 PFIZER INC. $3,246.76 02/26/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228825808
Principal investigator 1 PFIZER INC. $20,794.62 02/26/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228825849
Principal investigator 1 PFIZER INC. $65,620.20 02/25/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228826331
Principal investigator 1 ModernaTX, Inc. $3,000.00 02/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009750
Principal investigator 1 Bavarian Nordic A/S $74.00 02/21/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214082
Principal investigator 1 Bavarian Nordic A/S $271.63 02/21/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214084
Principal investigator 1 Bavarian Nordic A/S $74.00 02/21/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214186
Principal investigator 1 Bavarian Nordic A/S $231.88 02/21/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214188
Principal investigator 1 Bavarian Nordic A/S $483.63 02/21/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214190
Principal investigator 1 Bavarian Nordic A/S $271.63 02/21/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214192
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $241.30 02/21/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068085
Principal investigator 1 ModernaTX, Inc. $4,091.62 02/21/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992790
Principal investigator 1 ModernaTX, Inc. $35,708.64 02/21/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992842
Principal investigator 1 PFIZER INC. $793.20 02/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704956
Principal investigator 1 PFIZER INC. $100.00 02/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705010
Principal investigator 1 PFIZER INC. $1,894.87 02/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705102
Principal investigator 1 PFIZER INC. $5,110.66 02/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228826408
Principal investigator 1 PFIZER INC. $1,125.91 02/19/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228827590
Principal investigator 1 ModernaTX, Inc. $50.00 02/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992508
Principal investigator 1 ModernaTX, Inc. $4,372.50 02/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992792
Principal investigator 1 PFIZER INC. $811.69 02/12/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228826322
Principal investigator 1 PFIZER INC. $1,216.67 02/12/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228827596
Principal investigator 1 PFIZER INC. $447.85 02/08/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228825804
Recipient SANOFI US SERVICES INC. $323.11 02/08/2025 Covered Recipient Physician A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226117366
Recipient SANOFI US SERVICES INC. $398.62 02/08/2025 Covered Recipient Physician A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226117373
Recipient SANOFI US SERVICES INC. $630.54 02/08/2025 Covered Recipient Physician A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226117378
Recipient SANOFI US SERVICES INC. $69.00 02/08/2025 Covered Recipient Physician A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226117403
Recipient SANOFI US SERVICES INC. $69.00 02/08/2025 Covered Recipient Physician A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226117409
Recipient SANOFI US SERVICES INC. $74.50 02/08/2025 Covered Recipient Physician A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226117415
Principal investigator 1 ModernaTX, Inc. $15,000.00 02/07/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009734
Recipient SANOFI US SERVICES INC. $69.00 02/07/2025 Covered Recipient Physician A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226117385
Recipient SANOFI US SERVICES INC. $85.00 02/07/2025 Covered Recipient Physician A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226117391
Recipient SANOFI US SERVICES INC. $102.00 02/07/2025 Covered Recipient Physician A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226117397
Principal investigator 1 ABBVIE INC. $1,349.13 02/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202445039
Principal investigator 1 Bavarian Nordic A/S $74.00 02/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214178
Principal investigator 1 Bavarian Nordic A/S $331.88 02/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214194
Principal investigator 1 Bavarian Nordic A/S $231.88 02/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214198
Principal investigator 1 ModernaTX, Inc. $1,500.00 02/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252992488
Principal investigator 1 ModernaTX, Inc. $500.00 02/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252992490
Principal investigator 1 ModernaTX, Inc. $1,950.00 02/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252992630
Principal investigator 1 ModernaTX, Inc. $626.00 02/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252992772
Principal investigator 1 PFIZER INC. $150.00 02/05/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228827582
Principal investigator 1 PFIZER INC. $2,350.00 02/04/2025 Non-covered Recipient Entity
DM Clinical ResearchCyfair
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707485
Principal investigator 1 PFIZER INC. $726.10 02/04/2025 Non-covered Recipient Entity
DM Clinical ResearchCyfair
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707670
Principal investigator 1 PFIZER INC. $317.00 02/04/2025 Non-covered Recipient Entity
DM Clinical ResearchCyfair
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707840
Principal investigator 1 PFIZER INC. $317.00 02/04/2025 Non-covered Recipient Entity
DM Clinical Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228827859
Principal investigator 1 PFIZER INC. $726.10 02/04/2025 Non-covered Recipient Entity
DM Clinical Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228828775
Principal investigator 1 Bavarian Nordic A/S $74.00 02/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214200
Principal investigator 1 Bavarian Nordic A/S $231.88 02/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214202
Principal investigator 1 ModernaTX, Inc. $550.00 02/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992506
Principal investigator 1 ModernaTX, Inc. $2,858.88 02/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992658
Principal investigator 1 ModernaTX, Inc. $2,782.50 02/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992664
Principal investigator 1 ModernaTX, Inc. $500.00 02/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992878
Principal investigator 1 Seqirus USA Inc $1,019.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296608
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296610
Principal investigator 1 Seqirus USA Inc $1,019.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296618
Principal investigator 1 Seqirus USA Inc $1,019.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296620
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296622
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296624
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296626
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296628
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296630
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296632
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296634
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296636
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296640
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296642
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296644
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296646
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296648
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296650
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296652
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296654
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296656
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296658
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296660
Principal investigator 1 Seqirus USA Inc $508.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296662
Principal investigator 1 Seqirus USA Inc $1,019.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296688
Principal investigator 1 Seqirus USA Inc $1,019.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296690
Principal investigator 1 Seqirus USA Inc $1,019.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296692
Principal investigator 1 Seqirus USA Inc $1,019.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296694
Principal investigator 1 Seqirus USA Inc $1,019.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296696
Principal investigator 1 Seqirus USA Inc $1,019.00 02/03/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296698
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $241.30 01/31/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067159
Principal investigator 1 PFIZER INC. $837.08 01/31/2025 Non-covered Recipient Entity
DM Clinical Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228814626
Principal investigator 1 PFIZER INC. $981.24 01/31/2025 Non-covered Recipient Entity
DM Clinical Research
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228815363
Principal investigator 1 ModernaTX, Inc. $4,499.04 01/29/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252992738
Principal investigator 1 PFIZER INC. $10,938.98 01/29/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228832821
Principal investigator 1 PFIZER INC. $20,506.00 01/28/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228833026
Principal investigator 1 ModernaTX, Inc. $2,371.20 01/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009732
Principal investigator 1 ModernaTX, Inc. $13,984.00 01/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009736
Principal investigator 1 ModernaTX, Inc. $10,450.00 01/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253009766
Principal investigator 1 PFIZER INC. $887.77 01/25/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228833076
Principal investigator 1 ModernaTX, Inc. $34,778.65 01/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992666
Principal investigator 1 Bavarian Nordic A/S $231.88 01/22/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214204
Principal investigator 1 Bavarian Nordic A/S $74.00 01/22/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214206
Principal investigator 1 ModernaTX, Inc. $4,309.96 01/22/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992494
Principal investigator 1 ModernaTX, Inc. $6,094.90 01/22/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992774
Principal investigator 1 PFIZER INC. $8,271.22 01/22/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228832612
Principal investigator 1 Seqirus USA Inc $204.82 01/22/2025 Non-covered Recipient Entity
Dynamed Clinical Research
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185296700
Principal investigator 1 ModernaTX, Inc. $950.00 01/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992782
Principal investigator 1 ModernaTX, Inc. $546.56 01/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252992872
Principal investigator 1 PFIZER INC. $16,305.35 01/15/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228832472
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $3,064.70 01/14/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067155
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $68.00 01/14/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067157
Principal investigator 1 PFIZER INC. $1,435.00 01/13/2025 Non-covered Recipient Entity
DM Clinical Research Cyfair
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228827913
Principal investigator 1 Bavarian Nordic A/S $2,610.00 01/10/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214210
Principal investigator 1 ModernaTX, Inc. $2,150.00 01/10/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults No dispute reported 06/30/2026 1252992520
Principal investigator 1 Amgen Inc. $196,845.68 01/09/2025 Non-covered Recipient Entity
DM CLINICAL RESEARCH - CYFAIR CLINICAL RESEARCH CENTER
A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM No dispute reported 06/30/2026 1246640831
Principal investigator 1 Bavarian Nordic A/S $1,802.00 01/08/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214208
Principal investigator 1 Bavarian Nordic A/S $300.00 01/08/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214212
Principal investigator 1 Bavarian Nordic A/S $650.00 01/08/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214214
Principal investigator 1 PFIZER INC. $1,435.00 01/06/2025 Non-covered Recipient Entity
DM Clinical Research Cyfair
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228707666
Principal investigator 1 AstraZeneca UK Limited $11,677.00 01/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185538382
Principal investigator 1 ModernaTX, Inc. $9,158.67 01/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252992496
Principal investigator 1 ModernaTX, Inc. $7,081.30 01/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252992612
Principal investigator 1 ModernaTX, Inc. $150.00 01/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults No dispute reported 06/30/2026 1252992670
Principal investigator 1 ModernaTX, Inc. $3,568.57 01/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults No dispute reported 06/30/2026 1252992802
Principal investigator 1 ABBVIE INC. $1,656.93 01/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202434958
Principal investigator 1 ABBVIE INC. $355.50 01/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202434961
Principal investigator 1 PFIZER INC. $46.38 01/01/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704798
Principal investigator 1 PFIZER INC. $247.00 01/01/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228704802
Principal investigator 1 PFIZER INC. $1,300.77 01/01/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP dba DM Clinical Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705004
Principal investigator 1 PFIZER INC. $1,500.00 01/01/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA COVID19 VACCINE AND A RECOMBINANT INFLUENZA VACCINE ADMINISTERED AS A SINGLE INJECTION IN HEALTHY ADULTS 50 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1228832467
Principal investigator 1 PFIZER INC. $22,963.90 01/01/2025 Non-covered Recipient Entity
Dynamed Clinical Research LP
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228832816